Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9-36 Amide at the GLP-1 Receptor

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Li, Naichang ^a,b   Lu, Jing ^a   Willars, Gary B ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DICHLORO 2 METHYLSULFONYL 3 N TER BUTYLAMINOQUINOXALINE; DIPEPTIDYL PEPTIDASE IV; DRUG METABOLITE; EXENDIN 9-39; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE HORMONE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CALCIUM SIGNALING; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; INSULIN RELEASE; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR AFFINITY;

ADENOSINE MONOPHOSPHATE; ALLOSTERIC REGULATION; ANIMALS; BIOTRANSFORMATION; CALCIUM; CALCIUM SIGNALING; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; PEPTIDE FRAGMENTS; PEPTIDES; QUINOXALINES; RATS; RECEPTORS, GLUCAGON; SULFONES; TRANSFECTION;

EID: 84867677732     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047936     Document Type: Article

References (43)

1. Baggio LL, Drucker DJ, (2007) Biology of incretins: GLP-1 and GIP. Gastroenterol 132: 2131-2157.
2. Doyle ME, Egan JM, (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 113: 546-593.
3. Holst JJ, (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
4. Bavec A, Hallbrink M, Langel U, Zorko M, (2003) Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling. Regul Peptides 111: 137-144.
5. Hällbrink M, Holmqvist T, Olsson M, Östenson CG, Efendic S, et al. (2001) Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Gαs and Gαi/Gαo activation. Biochim Biophys Acta Protein Struct Mol Enzymol 1546: 79-86.
6. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, et al. (1999) Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140: 1132-1140.
7. Coopman K, Huang Y, Johnston N, Bradley SJ, Wilkinson GF, et al. (2010) Comparative effects of the endogenous agonist GLP-1 7-36 amide and a small molecule ago-allosteric agent 'compound 2' at the GLP-1 receptor. J Pharmacol Exp Ther 334: 795-808.
8. Tomas E, Habener JF, (2010) Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrin Met 21: 59-67.
9. Ørskov C, Wettergren A, Holst JJ, (1993) Biological effects and metabolic rates of glucagon-like peptide-1(7-36) amide and glucagon-like peptide-1(7-37) in healthy subjects are indistinguishable. Diabetes 42: 658-661.
10. Ørskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ, (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539.
11. Holst JJ, Vilsbøll T, Deacon CF, (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297: 127-136.
12. Mentlein R, Gallwitz B, Schmidt WE, (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835.
13. Meier JJ, Nauck MA, (2005) Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes-Metab Rev 21: 91-117.
14. Aroda VR, Henry RR, Han J, Huang W, Deyoung MB, et al. (2012) Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 34: 1247-1258.
15. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, et al. (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Nat Acad Sci U.S.A. 104: 937-942.
16. Koole C, Wootten D, Simms J, Valant C, Sridhar R, et al. (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78: 456-465.
17. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, et al. (1997) High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272: 21201-21206.
18. Knudsen LB, Pridal L, (1996) Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318: 429-435.
19. A, Theander S, Rubi B, Chaffard G, Wollheim CB, et al. (2004) Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 145: 667-678.
20. Dimitriadis GD, Richards SJ, Parry-Billings M, Leighton B, Newsholme EA, et al. (1991) β-adrenoceptor-agonist and insulin actions on glucose metabolism in rat skeletal muscle in different thyroid states. Biochem J 278: 587-593.
21. Huang Y, Wilkinson GF, Willars GB, (2010) Role of the signal peptide in the synthesis and processing of the glucagon-like peptide-1 receptor. Br J Pharmacol 159: 237-251.
22. Willars GB, Nahorski SR, (1995) Quantitative comparisons of muscarinic and bradykinin receptor-mediated Ins(1,4,5)P3 accumulation and Ca2+ signalling in human neuroblastoma cells. Br J Pharmacol 114: 1133-1142.
23. Brown BL, Albano JDM, Ekins RP, Sgherzi AM, Tampion W, (1971) A simple and sensitive saturation assay method for the measurement of adenosine 3959-cyclic monophosphate. Biochem J 121: 561-562.
24. Yamasaki-Mann M, Demuro A, Parker I, (2009) cADPR stimulates SERCA activity in Xenopus oocytes. Cell Calcium 45: 293-299.
25. Bootman MD, Roderick HL (2011) Using calcium imaging as a readout of GPCR activation. In: Receptor Signal Transduction Protocols. Humana Press. pp. 277-296.
26. Kurian N, Hall CJ, Wilkinson GF, Sullivan M, Tobin AB, et al. (2009) Full and partial agonists of muscarinic M3 receptors reveal single and oscillatory Ca2+ responses by β2-adrenoceptors. J Pharmacol Exp Ther 330: 502-512.
27. Flatt PR, Bailey CJ, Green BD, (2008) Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 13: 3648-3660.
28. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A, (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. Brit Med J 344: e1369.
29. Willard FS, Bueno AB, Sloop KW (2012) Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp Diabetes Res Article ID 709893.
30. Coopman K, Wallis R, Robb G, Brown A, Wilkinson GF, et al. (2011) Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor. Mol Endocrinol 25: 1804-1818.
31. Miller LJ, Chen Q, Lam PC-H, Pinon DI, Sexton PM, et al. (2011) Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling. J Biol Chem 286: 15895-15907.
32. Donnelly D, (2012) The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol 166: 27-41.
33. Cheong YH, Kim MK, Son MH, Kaang BK, (2012) Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently. Biochem Biophys Res Comm 417: 558-563.
34. Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, et al. (2006) Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 188: 481-492.
35. Zhou J, Wang X, Pineyro MA, Egan JM, (1999) Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48: 2358-2366.
36. Deacon CF, Johnsen AH, Holst JJ, (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957.
37. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, et al. (1995) Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.
38. Deacon CF, Plamboeck A, Moller S, Holst JJ, (2002) GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. The adipoinsular axis: effects of leptin on pancreatic β-cells. Am J Physiol Endocrinol Metab 282: E873-E879.
39. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, et al. (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53: 654-662.
40. Thorens B, (1992) Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide-1. Proc Natl Acad Sci USA 89: 8641-8645.
41. Erdogdua Ö, Nathansonb D, Sjöholmb Å, Nyströmb T, Zhanga Q, (2010) Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325: 26-35.
42. Knudsen LB, Hastrup S, Underwood CR, Wulff BS, Fleckner J, (2012) Functional importance of GLP-1 receptor species and expression levels in cell lines. Regul Peptides 175: 21-29.
43. Kenakin T, (2010) G protein coupled receptors as allosteric proteins and the role of allosteric modulators. J Recept Sig Transd 30 S1: 313-321.